Escherichia coli sequence type 131: Epidemiology and challenges in treatment

Zubair A. Qureshi, Yohei Doi

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Escherichia coli ST131 has emerged as a global epidemic, multidrug-resistant clone of E. coli causing extra-intestinal infections. It is now highly prevalent among fluoroquinolone-resistant and CTX-M ESBL-producing E. coli isolates worldwide. Humans are likely the primary reservoir of ST131. Factors associated with its acquisition include residence in long-term care facilities and recent receipt of antimicrobial agents. E. coli ST131 causes a wide array of infections ranging from cystitis to life-threatening sepsis. Fluoroquinolones and trimethoprim-sulfamethoxazole are no longer adequate options for empiric therapy when E. coli ST131 is suspected from risk factors and local epidemiology. Expanded-spectrum cephalosporins, piperacillin- tazobactam and carbapenems are options to treat serious non-ESBL-producing E. coli ST131 infections, while carbapenems are indicated for ESBL-producing infections. There is a growing interest in reevaluating oral agents including fosfomycin and pivmecillinam for less serious infections such as uncomplicated cystitis.

Original languageEnglish
Pages (from-to)597-609
Number of pages13
JournalExpert Review of Anti-Infective Therapy
Volume12
Issue number5
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

Epidemiology
Escherichia coli
Carbapenems
Cystitis
Fluoroquinolones
Infection
Amdinocillin Pivoxil
Fosfomycin
Therapeutics
Escherichia coli Infections
Sulfamethoxazole Drug Combination Trimethoprim
Long-Term Care
Cephalosporins
Anti-Infective Agents
Sepsis
Clone Cells

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

@article{22ab772d967c466a927f0da0c8763bae,
title = "Escherichia coli sequence type 131: Epidemiology and challenges in treatment",
abstract = "Escherichia coli ST131 has emerged as a global epidemic, multidrug-resistant clone of E. coli causing extra-intestinal infections. It is now highly prevalent among fluoroquinolone-resistant and CTX-M ESBL-producing E. coli isolates worldwide. Humans are likely the primary reservoir of ST131. Factors associated with its acquisition include residence in long-term care facilities and recent receipt of antimicrobial agents. E. coli ST131 causes a wide array of infections ranging from cystitis to life-threatening sepsis. Fluoroquinolones and trimethoprim-sulfamethoxazole are no longer adequate options for empiric therapy when E. coli ST131 is suspected from risk factors and local epidemiology. Expanded-spectrum cephalosporins, piperacillin- tazobactam and carbapenems are options to treat serious non-ESBL-producing E. coli ST131 infections, while carbapenems are indicated for ESBL-producing infections. There is a growing interest in reevaluating oral agents including fosfomycin and pivmecillinam for less serious infections such as uncomplicated cystitis.",
author = "Qureshi, {Zubair A.} and Yohei Doi",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/14787210.2014.899901",
language = "English",
volume = "12",
pages = "597--609",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "5",

}

Escherichia coli sequence type 131 : Epidemiology and challenges in treatment. / Qureshi, Zubair A.; Doi, Yohei.

In: Expert Review of Anti-Infective Therapy, Vol. 12, No. 5, 01.01.2014, p. 597-609.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Escherichia coli sequence type 131

T2 - Epidemiology and challenges in treatment

AU - Qureshi, Zubair A.

AU - Doi, Yohei

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Escherichia coli ST131 has emerged as a global epidemic, multidrug-resistant clone of E. coli causing extra-intestinal infections. It is now highly prevalent among fluoroquinolone-resistant and CTX-M ESBL-producing E. coli isolates worldwide. Humans are likely the primary reservoir of ST131. Factors associated with its acquisition include residence in long-term care facilities and recent receipt of antimicrobial agents. E. coli ST131 causes a wide array of infections ranging from cystitis to life-threatening sepsis. Fluoroquinolones and trimethoprim-sulfamethoxazole are no longer adequate options for empiric therapy when E. coli ST131 is suspected from risk factors and local epidemiology. Expanded-spectrum cephalosporins, piperacillin- tazobactam and carbapenems are options to treat serious non-ESBL-producing E. coli ST131 infections, while carbapenems are indicated for ESBL-producing infections. There is a growing interest in reevaluating oral agents including fosfomycin and pivmecillinam for less serious infections such as uncomplicated cystitis.

AB - Escherichia coli ST131 has emerged as a global epidemic, multidrug-resistant clone of E. coli causing extra-intestinal infections. It is now highly prevalent among fluoroquinolone-resistant and CTX-M ESBL-producing E. coli isolates worldwide. Humans are likely the primary reservoir of ST131. Factors associated with its acquisition include residence in long-term care facilities and recent receipt of antimicrobial agents. E. coli ST131 causes a wide array of infections ranging from cystitis to life-threatening sepsis. Fluoroquinolones and trimethoprim-sulfamethoxazole are no longer adequate options for empiric therapy when E. coli ST131 is suspected from risk factors and local epidemiology. Expanded-spectrum cephalosporins, piperacillin- tazobactam and carbapenems are options to treat serious non-ESBL-producing E. coli ST131 infections, while carbapenems are indicated for ESBL-producing infections. There is a growing interest in reevaluating oral agents including fosfomycin and pivmecillinam for less serious infections such as uncomplicated cystitis.

UR - http://www.scopus.com/inward/record.url?scp=84899009317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899009317&partnerID=8YFLogxK

U2 - 10.1586/14787210.2014.899901

DO - 10.1586/14787210.2014.899901

M3 - Review article

C2 - 24694052

AN - SCOPUS:84899009317

VL - 12

SP - 597

EP - 609

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 5

ER -